PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
LYT-100 demonstrated ~50% improvement versus pirfenidone in key adverse events at a comparable exposure level, which may lead to better patient compliance and improved treatment outcomes in...